To investigate the clinical effect of aluminium phosphate gel combined with omeprazole on peptic ulcer.

Forty-eight patients with peptic ulcer who received treatment in Jiaokou Hospital of Traditional Chinese Medicine from January 2016 to October 2019 were included in this study. They were divided into a control group and a study group according to the registration number at admission. Patients with an odd number were assigned to the control group,and those with an even number to the study group (n = 24/group). The control group was treated with oral omeprazole alone,while the study group was treated with oral omeprazole combined with oral aluminium phosphate gel. The course of treatment was 4 weeks in each group.Clinical efficacy, adverse reactions, gastrin and transforming growth factor-α levels were determined in both groups.

The overall efficacy in the study group was significantly higher than that in the control group [95.83% (23/24) vs. 79.17% (19/24), χ²= 5.079, P < 0.05]. Before treatment, there were no significant differences in gastrin [(137.5 ± 18.5) ng/L vs. (137.1 ± 18.8)ng/L, t = 0.143, P >0.05] and transforming growth factor-α [(4.3 ± 1.1) μg/L vs. (4.4 ± 1.2) μg/L, t = 0.156, P > 0.05] levels between study and control groups. After treatment,gastrin level in the study and control groups decreased [(67.6 ± 13.2) ng/L and (85.4 ± 20.3) ng/L ( t = 18.024, 17.569, both P < 0.05)] and transforming growth factor-α in the study and control groups increased [(7.2 ± 1.9) μg/L and (6.1 ± 1.5) μg/L, t = 5.268, 4.033,both P < 0.05)] compared with before treatment. After treatment, the changes in gastrin and transforming growth factor-α levels relative to before treatment were more obvious in the study group ( t = 8.269, 9.278, both P < 0.05) compared with the control group. The total incidence of adverse reactions in the study group was significantly lower than that in the control group [12.50% (3/24) vs. 25.00% (6/24), χ²= 6.539, P < 0.05].

Based on oral omeprazole, additional oral aluminium phosphate gel for the treatment of peptic ulcer can further improve clinical therapeutic effect by alleviating clinical symptoms, improving serological indexes and reducing adverse reactions, which is proven safe and reliable and is worth of clinical popularization.

Peptic ulcer; Aluminium phosphategel; Omeprazole; Therapeutic outcome; Safety; Gastrins; Transforming growth factor alpha; Proton pump inhibitors